Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hervycta
- Development stage
- Unknown
- Lead developer
- Dr. Reddy's Laboratories
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Hervycta is a biosimilar of the monoclonal antibody trastuzumab, developed by Dr. Reddy's Laboratories. It specifically targets the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in certain types of cancer. By binding to the extracellular domain of the HER2 receptor, Hervycta inhibits ligand-independent HER2 signaling and prevents the proteolytic cleavage of its extracellular domain, a marker of tumor progression. Additionally, it mediates antibody-dependent cellular cytotoxicity (ADCC) to induce the death of HER2-overexpressing cells. It is indicated for the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
- Brand names
- Hervycta
- Other names
- trastuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on Hervycta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hervycta.